Erste Asset Management GmbH Increases Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Erste Asset Management GmbH lifted its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 4.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,136 shares of the biotechnology company's stock after acquiring an additional 1,870 shares during the quarter. Erste Asset Management GmbH owned approximately 0.11% of United Therapeutics worth $16,957,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Newbridge Financial Services Group Inc. bought a new stake in shares of United Therapeutics in the 4th quarter worth $25,000. Brooklyn Investment Group purchased a new stake in United Therapeutics during the third quarter valued at about $33,000. MassMutual Private Wealth & Trust FSB lifted its holdings in United Therapeutics by 31.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock valued at $85,000 after purchasing an additional 58 shares during the last quarter. Jones Financial Companies Lllp lifted its holdings in United Therapeutics by 678.9% during the fourth quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company's stock valued at $104,000 after purchasing an additional 258 shares during the last quarter. Finally, SBI Securities Co. Ltd. purchased a new stake in United Therapeutics during the fourth quarter valued at about $131,000. Institutional investors own 94.08% of the company's stock.

United Therapeutics Price Performance

NASDAQ UTHR traded up $1.85 on Friday, reaching $307.24. 494,807 shares of the company's stock traded hands, compared to its average volume of 444,109. United Therapeutics Co. has a 12 month low of $221.53 and a 12 month high of $417.82. The stock has a 50-day simple moving average of $349.77 and a 200 day simple moving average of $358.54. The stock has a market cap of $13.80 billion, a PE ratio of 13.49, a P/E/G ratio of 0.97 and a beta of 0.64.

Remove Ads

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating analysts' consensus estimates of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $735.90 million for the quarter, compared to analysts' expectations of $734.74 million. During the same period last year, the business earned $4.36 earnings per share. As a group, analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current year.

Insider Buying and Selling at United Therapeutics

In other news, COO Michael Benkowitz sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $371.05, for a total value of $3,710,500.00. Following the transaction, the chief operating officer now owns 2,577 shares in the company, valued at approximately $956,195.85. This trade represents a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Louis W. Sullivan sold 26,209 shares of the firm's stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the completion of the transaction, the director now owns 5,051 shares in the company, valued at $1,885,134.22. This represents a 83.84 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 116,464 shares of company stock worth $42,396,244 over the last ninety days. Insiders own 11.90% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. HC Wainwright reaffirmed a "buy" rating and set a $425.00 price objective on shares of United Therapeutics in a report on Thursday, February 27th. StockNews.com downgraded shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Thursday, February 27th. Finally, UBS Group increased their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $388.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.